<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Guest Editorial

SABCS: 46 years at the forefront of clinical and translational research in breast cancer—and still growing

February 16, 2024

BYLINE DOWNLOAD PDF TABLE OF CONTENTS

The 2023 San Antonio Breast Cancer Symposium (SABCS), held Dec. 5-9 at the city’s Henry B. Gonzalez Convention Center, had a record-setting attendance with 10,874 registered attendees from 102 countries.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

Byline

Virginia Kaklamani, MD

<img width="300" height="300" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20300%20300'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2024/02/16004959/Virginia-Kaklamani_square-300x300.png" class="w_100p bgc_w lazy" alt="Virginia Kaklamani, MD" loading="lazy" data-srcset="https://cdn.cancerletter.com/media/2024/02/16004959/Virginia-Kaklamani_square-300x300.png 300w, https://cdn.cancerletter.com/media/2024/02/16004959/Virginia-Kaklamani_square-250x250.png 250w, https://cdn.cancerletter.com/media/2024/02/16004959/Virginia-Kaklamani_square.png 400w" data-sizes="(max-width: 300px) 100vw, 300px" />

Virginia Kaklamani, MD

Professor of medicine, Department of Hematology/Oncology, UT Health San Antonio; Leader of the Breast Cancer Program, UT Health San Antonio MD Anderson Cancer Center

Srivani Ravoori, PhD

<img width="300" height="300" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20300%20300'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2024/02/16014348/Srivani-Ravoori_square-300x300.png" class="w_100p bgc_w lazy" alt="Srivani Ravoori, PhD" loading="lazy" data-srcset="https://cdn.cancerletter.com/media/2024/02/16014348/Srivani-Ravoori_square-300x300.png 300w, https://cdn.cancerletter.com/media/2024/02/16014348/Srivani-Ravoori_square-250x250.png 250w, https://cdn.cancerletter.com/media/2024/02/16014348/Srivani-Ravoori_square.png 400w" data-sizes="(max-width: 300px) 100vw, 300px" />

Srivani Ravoori, PhD

Director of science communications, American Association for Cancer Research

Carlos L. Arteaga, MD

<img width="300" height="300" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20300%20300'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2023/04/14014144/Carlos-L-Arteaga_square-300x300.png" class="w_100p bgc_w lazy" alt="Carlos L. Arteaga, MD" loading="lazy" data-srcset="https://cdn.cancerletter.com/media/2023/04/14014144/Carlos-L-Arteaga_square-300x300.png 300w, https://cdn.cancerletter.com/media/2023/04/14014144/Carlos-L-Arteaga_square-250x250.png 250w, https://cdn.cancerletter.com/media/2023/04/14014144/Carlos-L-Arteaga_square.png 400w" data-sizes="(max-width: 300px) 100vw, 300px" />

Carlos L. Arteaga, MD

Director, Harold C. Simmons Comprehensive Cancer Center, Associate dean of oncology programs, Lisa K. Simmons Distinguished Chair in Comprehensive Oncology, UT Southwestern Medical Center

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Lynparza demonstrates survival benefit in early breast cancer, phase III trial data show

AstraZeneca and Merckannounced long-term results from the OlympiA phase III trial which showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival, invasive disease-free survival and distant disease-free survival for people with germline BRCA-mutated HER2-negative high-risk early breast cancer.

December 13, 2024

Clinical Roundup

Imlunestrant improves PFS in breast cancer, phase III data show

Eli Lilly and Co. announced results from the phase III EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader, in patients with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor.

December 13, 2024

Clinical Roundup

AI test is equivalent to Oncotype DX at predicting breast cancer recurrence, study shows

COTA Inc., PreciseDx, and Baptist Health South Florida announced study results validating that the artificial intelligence-enabled PreciseBreast test is equivalent to the Oncotype DX test at predicting breast cancer recurrence. The research was presented at the San Antonio Breast Cancer Symposium.

December 13, 2024

Clinical Roundup

MammaPrint test demonstrates utility in predicting chemotherapy benefit over five years

Agendia Inc. announced it will be presenting new data from the Real-World Data Registry, FLEX, demonstrating MammaPrint’s ability to predict chemotherapy benefit in patients with HR+HER2- early-stage breast cancer. The findings will be presented at the San Antonio Breast Cancer Symposium 2024. The MammaPrint test analyzes the 70 most important genes associated with breast cancer recurrence.

December 13, 2024

Clinical Roundup

Genetic disposition increases the risk of breast cancer metastasis

For over 50 years, scientists have been on a quest to identify which malignant mutations within the tumor allow rogue cells to break away from the primary tumor and travel through the bloodstream and lymphatic system to metastasize throughout the body. Now, new research suggests an alternative mechanism has been overlooked—elusive mutations driving metastasis may not be developing within the twisted DNA of tumors themselves, but within the patient’s regular, inherited DNA.

December 13, 2024

Clinical Roundup

Kisqali shows reduction in distant recurrence in early breast cancer, phase III data show

Novartis announced results from an updated analysis of the pivotal phase III NATALEE trial of Kisqali (ribociclib) that underscore the extended efficacy beyond the duration of treatment in combination with endocrine therapy. Results showed a sustained reduction in distant recurrence of 28.5% (HR=0.715; 95% CI 0.604-0.847; nominal P<0.0001), compared to ET alone, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer.

December 13, 2024